Digestive Diseases and Sciences

, Volume 42, Issue 9, pp 1969–1980

Protease Activity in a Hapten-Induced Model of Ulcerative Colitis in Rats

  • James V. Hawkins
  • Eva L. Emmel
  • Jennifer J. Feuer
  • Mark A. Nedelman
  • Catherine J. Harvey
  • Hilton J. Klein
  • Harry Rozmiarek
  • Ann R. Kennedy
  • Gary R. Lichtenstein
  • Paul C. Billings
Article
  • 172 Downloads

Abstract

Inflammatory bowel disease (IBD) is a painfuland debilitating condition affecting the mucosal liningof the colon and other areas of the gastrointestinaltract. IBD generally falls into two major categories: ulcerative colitis (UC) and Crohn's disease. Wehave utilized dinitrobenzenesulfonic acid (DNBS) toinduce experimental UC in rats. Histopathologic analysisindicates that DNBS induces a condition in animals similar to human UC. Biochemical resultsrevealed 6- to 10-fold elevated levels of serineprotease activity in colon tissue from animals with UCas compared with matched controls. We also observedelevated levels of protease activity in tissue samplesobtained from human patients with UC. Hence, our resultsdemonstrate that protease activity is increased inrodent and human UC. These proteases may play a significant role in destruction of colonictissue in IBD. Protease inhibitors that target serineproteases may be useful pharmacological agents to limittissue destruction in IBD.

PROTEASE ACTIVITY ULCERATIVE COLITIS 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Glickman RM: Inflammatory bowel disease: Ulcerative colitis and crohn's disease. In Harrison's Principles of Internal Medicine. KJ Isselbacher, et al (eds). New York, McGraw-Hill, 1994, pp 1403–1417Google Scholar
  2. 2.
    Podolsky DK: Inflammatory bowel disease. N Engl J Med 325:928–937, 1008–1016, 1991Google Scholar
  3. 3.
    Calkins BM, Mendeloff AI: The epidemiology of idiopathic inflammatory bowel disease. In Inflammatory Bowel Disease, 4th ed. JB Kirsner, RG Shorter (eds). Philadelphia, Williams and Wilkins, 1995, pp 31–68Google Scholar
  4. 4.
    Crawford JM: The gastrointestinal tract. In Robbins Pathologic Basis of Disease, 5th ed. RS Cotran, V Kumar, SL Robbins, FJ Schoen (eds). Philadelphia, WB Saunders, 1994, pp 755–829Google Scholar
  5. 5.
    Brynskov J, Nielsen OH, Ahnfelt-Ronne L, Bendtzen K: Cytokines and their natural regulation in inflammatory bowel disease. Dig Dis 12:290–304, 1994Google Scholar
  6. 6.
    Grisham MB: Oxidants and free radicals in inflammatory bowel disease. Lancet 344:859–861, 1994Google Scholar
  7. 7.
    Hodgson HJ: Immunological aspects of inflammatory bowel disease of the human gut. Agents Actions Special Conference Issue: C27–C31, 1992Google Scholar
  8. 8.
    Rudolph U, Finegold MJ, Rich SS, Harriman GR, Srinivasan Y, Brabet P, Boulay G, Bradley A, Birnbaumer L: Ulcerative colitis and adenocarcinoma of the colon in G alpha i2-deficient mice. Nature Genet 10:143–150, 1995Google Scholar
  9. 9.
    Bohe M: Pancreatic and granulocytic endoproteases in faecal extracts from patients with active ulcerative colitis. Scand J Gastroenterol 22:59–64, 1987Google Scholar
  10. 10.
    Bohe M, Genell S, Ohlsson K: Protease inhibitors in plasma and faecal extracts from patients with active inflammatory bowel disease. Scand J Gastroenterol 21:598–604, 1986Google Scholar
  11. 11.
    Ottonello L, Dapino P, Pastorino G, Vitale E, Dallegri F: The drug 5-aminosalicylic acid rescues alpha 1-proteinase inhibitor from the neutrophil oxidative inactivation. A possible contribution to its therapeutic action in ulcerative colitis. Digestion 51:140–145, 1992Google Scholar
  12. 12.
    Playford RJ, Hanby AM, Patel K, Calam J: Influence of inflammatory bowel disease on the distribution and concentration of pancreatic secretory trypsin inhibitor within the colon. Am J Pathol 146:310–316, 1995Google Scholar
  13. 13.
    Senda SY, Fujiyama Y, Bamba T, Hosoda S: Treatment of ulcerative colitis with camostat mesilate, a serine protease inhibitor. Intern Med 32:350–354, 1993Google Scholar
  14. 14.
    Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL: Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96:795–803, 1989Google Scholar
  15. 15.
    Elson CO, Sartor RB, Tennyson GS, Riddell RH: Experimental models of inflammatory bowel disease. Gastroenterology 109:1344–1367, 1995Google Scholar
  16. 16.
    Nahas F, Leskowitz S: The ability of hapten-conjugated cells to induce cell-mediated cytotoxicity is affected by the mode of hapten linkage. Cell Immunol 54:241–247, 1980Google Scholar
  17. 17.
    Prophet EB, Mills B, Arrington JB, Sobin LH (eds): Armed Forces Institute of Pathology, Laboratory Methods in Histotechnology. Washington, DC, American Registry of Pathology, 1992, p 55Google Scholar
  18. 18.
    Wallace JL, Keenan CM: An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am J Physiol 258:527–534, 1990Google Scholar
  19. 19.
    Krawisz JE, Sharon P, Stenson WF: Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 87:1344–1350, 1984Google Scholar
  20. 20.
    Laemmli UK: Cleavage of structural proteins during the assembly of bacteriophage T4, Nature 227:680–685, 1970Google Scholar
  21. 21.
    Billings PC, Habres JM: A growth regulated protease activity which is inhibited by the anticarcinogenic Bowman-Birk inhibitor. Proc Natl Acad Sci USA 89:3120–3124, 1992Google Scholar
  22. 22.
    Gomori G: Preparation of buffers for use in enzyme studies. Methods Enzymol 1:138–146, 1955Google Scholar
  23. 23.
    Billings PC, Newberne P, Kennedy AR: Protease inhibitor suppression of colon and anal gland carcinogenesis induced by dimethylhydrazine. Carcinogenesis 11:1083–1086, 1990Google Scholar
  24. 24.
    Billings PC, Habres JM, Liao DC, Tuttle SW: A protease activity in human fibroblasts which is inhibited by the anticarcinogenic Bowman-Birk protease inhibitor. Cancer Res 50:5539–5543, 1991Google Scholar
  25. 25.
    Moy LY, Billings PC: A proteolytic activity in a human breast cancer cell line which is inhibited by the anticarcinogenic Bowman-Birk protease inhibitor. Cancer Lett 85:205–210, 1994Google Scholar
  26. 26.
    Weiss SJ: Tissue destruction by neutrophils. N Engl J Med 320:365–376, 1989Google Scholar
  27. 27.
    Tikhonova TV, Larionova NI, Gladysheva IP, Kazanskaya NF: Bowman-Birk soybean inhibitor as an affinity ligand for isolation of leukocyte elastase: Inhibition of leukocyte elastase-mediated elastin hydrolysis. Biokhimiya 11:1669–1676, 1993Google Scholar
  28. 28.
    Larionova NI, Gladysheva IP, Tikhonova TV, Kazanskaya NF: Inhibition of cathepsin G and human granulocyte elastase by multiple forms of Bowman-Birk type soybean inhibitor. Biokhimiya 58:1437–1444, 1993Google Scholar

Copyright information

© Plenum Publishing Corporation 1997

Authors and Affiliations

  • James V. Hawkins
  • Eva L. Emmel
  • Jennifer J. Feuer
  • Mark A. Nedelman
  • Catherine J. Harvey
  • Hilton J. Klein
  • Harry Rozmiarek
  • Ann R. Kennedy
  • Gary R. Lichtenstein
  • Paul C. Billings

There are no affiliations available

Personalised recommendations